ClinicalTrials.Veeva

Menu
H

Hospital Universitario de La Ribera | Neurophysiology and Sleep Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Orforglipron
LY3502970
E2086
Trastuzumab
Tirzepatide
Retatrutide
Eloralintide
LY3841136
LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants...

Enrolling
Overweight
Obesity
Drug: Eloralintide
Drug: Placebo
Locations recently updated

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiova...

Enrolling
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of exce...

Enrolling
Narcolepsy
Drug: E2086
Drug: Placebo
Locations recently updated

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Daiichi Sankyo logo
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems